Subject characteristics and outcomes of sweat chloride and NPD testing
| Groups | N | Age, mean±SD | Gender: male, n (%) | FEV1% predicted, mean±SD* | Sweat chloride (mmol/L) | NPD: ΔCl-free+Iso (mV) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Normal | Borderline | Abnormal | Normal | Borderline | Abnormal | |||||
| RESP† | 68 | 38.9±15.1 | 19 (27.9%) | 80±21 | 46 (67.6%) | 8 (11.8%) | 14 (20.6%) | 35 (51.5%) | 13 (19.1%) | 20 (29.4%) |
| PANC | 42 | 24.3±12.8 | 16 (38.1%) | 93±16 | 36 (85.7%) | 4 (9.5%) | 2 (4.8%) | 24 (57.1%) | 6 (14.3%) | 12 (28.6%) |
| AZOOSP | 92 | 34.8±5.3 | 92 (100%) | 94±14 | 39 (42.4%) | 34 (36.9%) | 19 (20.7%) | 38 (41.3%) | 19 (20.7%) | 35 (38.0%) |
| CONTROL | 104 | 31.7±8.2 | 51 (49.0%) | 91±10 | 100 (96.2%) | 4 (3.8%) | 0 | 95 (91.3%) | 9 (8.7%) | 0 |
| HETERO | 52 | 38.9±8.6 | 21 (40.4%) | 92±13 | 41 (78.8%) | 11 (21.2%) | 0 | 43 (82.7%) | 9 (17.3%) | 0 |
| CFPS‡ | 64 | 32.3±12.5 | 33 (51.6%) | 72±25 | 12 (18.8%) | 11 (17.2%) | 41 (64.0%) | 0 | 3 (4.7%) | 61 (95.3%) |
| CFPI | 43 | 22.5±10.8 | 31 (72.1%) | 64±20 | 0 | 0 | 43 (100%) | 0 | 0 | 43 (100%) |
*Pulmonary function was evaluated by standard pulmonary function methods. Forced expiratory volume in 1 s was expressed as a percentage of the predicted values for height and sex (FEV1% predicted).24 ,25
†See Gonska et al9 for additional clinical details.
‡Among the 12/64 (18.8%) CFPS subjects with normal sweat test, all except one had abnormal NPD: five had previous abnormal sweat test (four with abnormal NPD, one borderline NPD), four were diagnosable by genotype as well as abnormal NPD, and three had abnormal NPD only. Of the 11/64 (17.2%) CFPS subjects with borderline sweat test, all except one had abnormal NPD also: eight had previously abnormal sweat chloride (seven had abnormal NPD, one borderline NPD) and three had abnormal NPD only.
AZOOSP, obstructive azoospermia; CF, cystic fibrosis; CFPI, pancreatic insufficient; CFPS, pancreatic sufficient; CONROL, healthy controls; FEV1, forced expiratory volume in 1 s; HETERO, heterozygotes; NPD, nasal potential difference; PANC, chronic/recurrent pancreatitis; RESP, chronic sino-pulmonary disease.